Tenaya Therapeutics Inc (TNYA)

Currency in USD
0.770
+0.031(+4.19%)
Closed·
0.7700.000(-0.03%)
·

Tenaya Therapeutics Inc Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Contact Information

Address
171 Oyster Point Boulevard Suite 500, South San Francisco, 94080, United States
Phone
650 825 6990

Top Executives

Name
Title
Since
Age
Faraz AliCEO, Interim Principal Financial Officer & Director202453
Deepak SrivastavaScientific Founder, Chairman of Scientific Advisory Board & Director201659
Eric N. OlsonScientific Founder & Member of Scientific Advisory Board--
Jeffrey T. WalshIndependent Director202060
June H. LeeIndependent Director202160
Timothy HoeyMember of Scientific Advisory Board202467
R. Sanders WilliamsIndependent Director201677
Catherine Stehman-BreenIndependent Director202063
Jonathan S. WeissmanMember of Scientific Advisory Board--
Mark A. KayMember of Scientific Advisory Board-67
Douglas L. MannMember of Scientific Advisory Board--
Karah Herdman ParschauerIndependent Director202148
Amy L. BurroughsIndependent Director202255
Christine Edry SeidmanMember of Scientific Advisory Board2023-
Alexander MarsonMember of Scientific Advisory Board2023-
Barry J. ByrneMember of Scientific Advisory Board2024-
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.